Sodium Phosphate Cotransporter

Sodium phosphate cotransporters are a type of membrane protein that primarily regulate the co-transport of sodium (Na⁺) and phosphate (PO₄^3-). These transporters utilize the concentration gradient of sodium ions inside and outside the cell, employing an active transport mechanism to facilitate the movement of phosphate across the cell membrane, playing a central role in the distribution and utilization of phosphate within the body. In mammals, these transporters are primarily composed of members from the SLC34 and SLC20 families. The SLC34 family includes NaPi-IIa, NaPi-IIb, and NaPi-IIc, which are primarily expressed in the apical membrane of epithelial cells in the kidneys and intestines, responsible for the reabsorption and intake of phosphate, constituting the rate-limiting step in trans-epithelial phosphate transport. The SLC20 family includes Pit-1 and Pit-2, which were initially identified as receptors for retroviruses, but were later found to also function as sodium phosphate cotransporters, mainly involved in regulating intracellular phosphate levels and widely expressed in various tissues such as bones, kidneys, and intestines. In the cardiovascular system, Pit-1 may play a role in vascular calcification under conditions of hyperphosphatemia.
Sodium phosphate cotransporters are associated with renal metabolic diseases such as phosphate wasting syndrome, making them potential therapeutic targets^[1]^[2].

References:

[1]. Murer H, et al. The sodium phosphate cotransporter family SLC34. Pflugers Arch. 2004 Feb;447(5):763-7. [Content Brief]

[2]. Collins JF, et al. The SLC20 family of proteins: dual functions as sodium-phosphate cotransporters and viral receptors. Pflugers Arch. 2004 Feb;447(5):647-52. [Content Brief]

Sodium Phosphate Cotransporter Inhibitors (2)

Sodium Phosphate Cotransporter Related Products (4):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P99970

Lifastuzumab		99.08%
Lifastuzumab is a humanized anti-NaPi2b IgG1 monoclonal antibody. Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) (HY-15162) through ADC Linker to form an antibody-drug conjugate (ADC) Lifastuzumab vedotin (HY-P99705) with anticancer activity. Lifastuzumab vedotin can be studied in research for non-small cell lung cancer and ovarian cancer. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-159978

EOS789	Inhibitor	99.14%
EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC₅₀ values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC₅₀ values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD).

HY-182689

LY3358966
LY3358966 is an orally active sodium-dependent phosphate cotransporter 2b (NPT2b) inhibitor with a human IC₅₀ of 32.4 nM, mouse IC₅₀ of 43.9 nM, and rat of IC₅₀ 26.8 nM. LY3358966 inhibits NPT2b-mediated intestinal phosphate transport, decreases acute phosphate uptake into plasma, and increases fecal phosphate excretion. LY3358966 can be used for the research of renal disease.

HY-142957

NaPi2b-IN-1	Inhibitor
NaPi2b-IN-1 is a potent and orally active inhibitor of sodium-dependent phosphate transport protein 2b (NaPi2b) with an IC₅₀ of 64 nM. NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. NaPi2b-IN-1 has the potential for the research of hyperphosphatemia.

Name
Email *

	Sorry, but the email address you supplied was invalid.